- Home
- NUVL vs BOX Comparison
NUVL vs BOX Comparison
Compare NUVL & BOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- BOX
- Stock Information
- Founded
- NUVL 2017
- BOX 2005
- Country
- NUVL United States
- BOX United States
- Employees
- NUVL N/A
- BOX N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- BOX Computer Software: Prepackaged Software
- Sector
- NUVL Health Care
- BOX Technology
- Exchange
- NUVL Nasdaq
- BOX Nasdaq
- Market Cap
- NUVL 5.4B
- BOX 5.4B
- IPO Year
- NUVL 2021
- BOX 2015
- Fundamental
- Price
- NUVL $80.48
- BOX $33.22
- Analyst Decision
- NUVL Strong Buy
- BOX Buy
- Analyst Count
- NUVL 10
- BOX 8
- Target Price
- NUVL $119.60
- BOX $38.50
- AVG Volume (30 Days)
- NUVL 582.7K
- BOX 2.1M
- Earning Date
- NUVL 08-07-2025
- BOX 08-26-2025
- Dividend Yield
- NUVL N/A
- BOX N/A
- EPS Growth
- NUVL N/A
- BOX 77.37
- EPS
- NUVL N/A
- BOX 1.30
- Revenue
- NUVL N/A
- BOX $1,101,744,000.00
- Revenue This Year
- NUVL N/A
- BOX $8.52
- Revenue Next Year
- NUVL N/A
- BOX $7.44
- P/E Ratio
- NUVL N/A
- BOX $25.62
- Revenue Growth
- NUVL N/A
- BOX 4.88
- 52 Week Low
- NUVL $55.54
- BOX $24.63
- 52 Week High
- NUVL $113.51
- BOX $38.80
- Technical
- Relative Strength Index (RSI)
- NUVL 59.85
- BOX 37.45
- Support Level
- NUVL $76.27
- BOX $32.69
- Resistance Level
- NUVL $80.90
- BOX $34.39
- Average True Range (ATR)
- NUVL 2.55
- BOX 0.70
- MACD
- NUVL 0.19
- BOX -0.40
- Stochastic Oscillator
- NUVL 81.61
- BOX 10.08
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About BOX Box Inc.
Box is a cloud-based content management platform that provides storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file, sync, and share provider. Over time, it built out and acquired workflow and security tools to evolve the pure-play FSS business into a content management business. Most recently, Box has been pursuing an AI-powered, intelligent content management strategy that can allow for metadata extraction and workflow automation.